Clinical Trial Update: A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134) [Phase 1]

View source ↗

Summary

Phase 1 pediatric trial of aprepitant (MK-0869) and fosaprepitant (MK-0517) in chemotherapy-induced nausea and vomiting; study terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chemotherapy-induced Nausea and Vomiting

Drugs mentioned

• Aprepitant (aprepitant)
• FOSAPREPITANT (FOSAPREPITANT DIMEGLUMINE)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Chemotherapy-Induced Nausea and Vomiting | Phase 1 | Status: TERMINATED | Results posted: 2014-11-18